Currently out of the existing stock ratings of Ashwani Verma, 35 are a BUY (70%), 12 are a HOLD (24%), 3 are a SELL (6%).

Ashwani Verma

Work Performance Price Targets & Ratings Chart

Analyst Ashwani Verma, currently employed at UBS, carries an average stock price target met ratio of 68.69% that have a potential upside of 24.72% achieved within 164 days.

Ashwani Verma’s has documented 100 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TEVA, Teva Pharma Industries Ltd ADR at 03-Sep-2024.

Wall Street Analyst Ashwani Verma

Analyst best performing recommendations are on RANI (RANI THERAPEUTICS HOLDINGS).
The best stock recommendation documented was for RANI (RANI THERAPEUTICS HOLDINGS) at 11/15/2023. The price target of $4 was fulfilled within 146 days with a profit of $2.01 (101.01%) receiving and performance score of 6.92.

Average potential price target upside

of $61.15 (23.81%) on UTHR (UNITED THERAPEUTICS).
of $25.48 (60.99%) on CYTK (CYTOKINETICS).
of $24 (23.56%) on NBIX (NEUROCRINE BIOSCIENCES).

ITCI Intracellular Th HZNP Horizon Pharma PLC CHRS Coherus BioSciences JAZZ Jazz Pharmaceuticals PLC RPRX Royalty Pharma Plc TEVA Teva Pharma Industries Ltd ADR VTRS Viatris CYTK Cytokinetics KRTX Karuna Therapeutics NBIX Neurocrine Biosciences UTHR United Therapeutics ALKS Alkermes Plc AXSM Axsome Therapeutics RANI Rani Therapeutics Holdings

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jessica Fye (JPMORGAN)